RT Journal Article
SR Electronic
T1 Immunity to SARS-CoV-2 persists 9 months post-symptoms with an altered T cell phenotype compared to influenza A virus-specific memory
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.08.21258518
DO 10.1101/2021.06.08.21258518
A1 Law, Jaclyn C.
A1 Girard, Melanie
A1 Chao, Gary Y. C.
A1 Ward, Lesley A.
A1 Isho, Baweleta
A1 Rathod, Bhavisha
A1 Colwill, Karen
A1 Li, Zhijie
A1 Rini, James M.
A1 Yue, Feng Yun
A1 Mubareka, Samira
A1 McGeer, Allison J.
A1 Ostrowski, Mario A.
A1 Gommerman, Jennifer L.
A1 Gingras, Anne-Claude
A1 Watts, Tania H.
YR 2021
UL http://medrxiv.org/content/early/2021/06/10/2021.06.08.21258518.abstract
AB SARS-CoV-2 induces T cell, B cell and antibody responses that are detected for several months in recovered individuals. Whether this response resembles a typical respiratory viral infection is a matter of debate. Here we followed T cell and antibody responses in 24 mainly non-hospitalized SARS-CoV-2 recovered subjects at two time points (median of 45- and 145-days post-symptom onset). Antibody responses were detected in 95% of subjects, with a strong correlation between plasma and salivary anti-S and anti-RBD IgG, as well as a correlation between circulating T follicular helper cells and the SARS-CoV-2-specific IgG response. Based on intracellular cytokine production or proliferation, CD4+ T cell responses to SARS-CoV-2 were detected in all subjects, decaying with a half-life of 5-6 months for S-specific IL-2-producing cells. CD4+ responses were largely of the T helper 1 phenotype, but with a lower ratio of IFN-γ: IL-2 producing cells and a lower frequency of CD8+: CD4+ T cells compared to influenza A virus-(IAV)-specific memory responses within the same subjects. Analysis of secreted molecules also revealed a lower ratio of IFN-γ: IL-2 and IFN-γ: IL-6 and an altered cytotoxic profile for S- and N-specific compared to IAV-specific responses. These data suggest that the memory T-cell phenotype after a single infection with SARS-CoV-2 persists over time, with an altered cytokine and cytotoxic profile compared to long term memory to IAV within the same subjects.One Sentence Summary Immunity to SARS-CoV-2 in a cohort of patients, mainly with mild COVID-19 disease, persists to 9 months with an altered T cell cytokine and cytotoxicity profile compared to influenza A virus-specific memory T cells from the same subjects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a grant from the Canadian Institutes of Health Research (CIHR) Grant # VR1-172711 to T.H.W., J.G., J. M.R., M.O, A.C.G, S.M and A.J.M. with an additional supplement from the COVID-19 Immunity task force. J.L.G. received funding from Ontario Together grant. Patient recruitment was funded by RIS-COV CIHR grant number No. RN419944-439999. JCL was funded by a Queen Elizabeth 2nd Scholarship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Individuals who had recovered from COVID-19 as confirmed by positive nasopharyngeal COVID-19 PCR upon presentation, were recruited to RISC-CoV through participating hospitals in the Toronto Invasive Bacterial Diseases Network, with informed consent, to donate blood and saliva, as approved by the University of Toronto Research Ethics Board (REB protocol number 00027673 to THW). All human subjects research was done in compliance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and materials availability: All data files, including Flow cytometry FCS plots, are available from the authors upon request.